Leukocytapheresis for the treatment of active pouchitis: A pilot study

Journal of Gastroenterology

Volumn 43, Issue 7, 2008, Pages 571-575

  Araki, Yasumi ^a   Mitsuyama, Keiichi ^b   Nagae, Takaaki ^a   Tou, Yuji ^a   Nakagawa, Motonori ^a   Iwatani, Yasue ^a   Harada, Masakazu ^a   Ozasa, Hiroyuki ^a   Sata, Michio ^b   Noake, Toshihiro ^a  

^a Kurume Coloproctology Center   (Japan)

^b KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Ileal pouch anal anastomosis; Leukocytapheresis pouchitis; Ulcerative colitis

Indexed keywords

MESALAZINE; METRONIDAZOLE; PREDNISOLONE; PROBIOTIC AGENT;

ADULT; AGED; ARTICLE; BIFIDOBACTERIUM; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; DISEASE ACTIVITY; DRUG RESPONSE; FEMALE; HUMAN; ILEITIS; ILEOANAL ANASTOMOSIS; LEUKAPHERESIS; MALE; PILOT STUDY; PRIORITY JOURNAL; PROCTOCOLECTOMY; REMISSION; ULCERATIVE COLITIS;

ADULT; AGED; COLECTOMY; COLITIS, ULCERATIVE; COLONIC POUCHES; FEMALE; HUMANS; LEUKAPHERESIS; MALE; MIDDLE AGED; POUCHITIS;

EID: 48449084342     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-008-2199-0     Document Type: Article

References (30)

1. Sartor RB. Mechanisms of disease: Pathogenesis of Crohn's disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol 2006;3:390-407.
2. Sandborn WJ. Pouchitis following ileal pouch-anal anastomosis: definition, pathogenesis, and treatment. Gastroenterology 1994;107:1856-1860.
3. Hurst RD, Molinari M, Chung TP, Rubin M, Michelassi F. Prospective study of the incidence, timing and treatment of pouchitis in 104 consecutive patients after restorative proctocolectomy. Arch Surg 1996;131:497-502.
4. Meagher AP, Farouk R, Dozois RR, Kelly KA, Pemberton JH. Ileal pouch-anal anastomosis for chronic ulcerative colitis: Complications and long-term outcome in 1310 patients. Br J Surg 1998;85:800-803.
5. Pardi DS, Sandborn WJ. Systematic review: The management of pouchitis. Aliment Pharmacol Ther 2006;23:1087-1096.
6. Akerlund JE, Lofberg R. Pouchitis. Curr Opin Gastroenterol 2004;20:341-344.
7. Mimura T, Rizzello F, Helwig U, Poggioli G, Schreiber S, Talbot IC, et al. Four-week open-label trial of metronidazole and ciprofloxacin for the treatment of recurrent or refractory pouchitis. Aliment Pharmacol Ther 2002;16:909-917.
8. Mimura T, Rizzello F, Helwig U, Poggioli G, Schreiber S, Talbot IC, et al. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 2004;53:108-114.
9. Tremaine WJ, Sandborn WJ, Wolff BG, Carpenter HA, Zinsmeister AR, Metzger PP. Bismuth carbomer foam enemas for active chronic pouchitis: A randomized, double-blind, placebocontrolled trial. Aliment Pharmacol Ther 1997;11:1041-1046.
10. Miner P, Wedel M, Bane B, Bradley J. An enema formulation of alicaforsen, an antisense inhibitor of intercellular adhesion molecule-1, in the treatment of chronic, unremitting pouchitis. Aliment Pharmacol Ther 2004;19:281-286.
11. Shen B, Fazio VW, Remzi FH, Delaney CP, Bennett AE, Achkar JP, et al. Comprehensive evaluation of inflammatory and noninflammatory sequelae of ileal pouch-anal anastomoses. Am J Gastroenterol 2005;100:93-101.
12. Viscido A, Habib FI, Kohn A, Papi C, Marcheggiano A, Pimpo MT, et al. Infliximab in refractory pouchitis complicated by fistulae following ileo-anal pouch for ulcerative colitis. Aliment Pharmacol Ther 2003;17:1263-1271.
13. Sandborn WJ. Pouchitis in the Kock continent ileostomy and the ileoanal pouch. In: Kirsner JB, editor. Inflammatory bowel disease. 5th ed. Philadelphia: Saunders; 2000. p. 736-747.
14. Hibi T, Sakuraba A. Is there a role for apheresis in gastrointestinal disorders? Nat Clin Pract Gastroenterol Hepatol 2005;2:200-201.
15. Kanai T, Hibi T, Watanabe M. The logics of leukocytapheresis as a natural biological therapy for inflammatory bowel disease. Expert Opin Biol Ther 2006;6:453-466.
16. Sawada K, Muto T, Shimoyama T, Satomi M, Sawada T, Nagawa H, et al. Multicenter randomized controlled trial for the treatment of ulcerative colitis with a leukocytapheresis column. Curr Pharm Des 2003;9:307-321.
17. Fujimoto E, Fujimoto N, Kuroda K, Tajima S. Leukocytapheresis treatment for pyoderma gangrenosum. Br J Dermatol 2004;151:1090-1092.
18. Fukunaga K, Sawada K, Fukuda Y, Matoba Y, Onishi K, Fukui S, et al. A case report: First case of filtration leukocytapheresis for a patient of aortitis syndrome associated with ulcerative colitis. Ther Apher 2002;6:93-98.
19. Sandborn WJ, Tremaine WJ, Batts KP, Pemberton JH, Phillips SF. Pouchitis after ileal pouch-anal anastomosis: A Pouchitis Disease Activity Index. Mayo Clin Proc 1994;69:409-415.
20. Sawada K, Ohnishi K, Kosaka T, Chikano S, Yokota Y, Egashira A, et al. Leukocytapheresis with leukocyte removal filter as new therapy for ulcerative colitis. Ther Apher 1997;1:207-211.
21. Patel RT, Bain I, Youngs D, Keighley MR. Cytokine production in pouchitis is similar to that in ulcerative colitis. Dis Colon Rectum 1995;38:831-837.
22. Bulois P, Tremaine WJ, Maunoury V, Gambiez L, Hafraoui S, Leteurtre L, et al. Pouchitis is associated with mucosal imbalance between interleukin-8 and interleukin-10. Inflamm Bowel Dis 2000;6:157-164.
23. Evgenikos N, Bartolo DC, Hamer-Hodges DW, Ghosh S. Assessment of ileoanal pouch inflammation by interleukin 1beta and interleukin 8 concentrations in the gut lumen. Dis Colon Rectum 2002;45:249-255.
24. Kuhbacher T, Gionchetti P, Hampe J, Helwig U, Rosenstiel P, Campieri M, et al. Activation of signal-transducer and activator of transcription 1 (STAT1) in pouchitis. Clin Exp Immunol 2001;123:395-401.
25. Mitsuyama K, Suzuki A, Matsumoto S, Tomiyasu N, Takaki K, Takedatsu H, et al. Diminished cytokine signalling against bacterial components in mononuclear leucocytes from ulcerative colitis patients after leukocytapheresis. Clin Exp Immunol 2005;141:130-140.
26. Andoh A, Ogawa A, Kitamura K, Inatomi O, Fujino S, Tsujikawa T, et al. Suppression of interleukin-1beta-and tumor necrosis factor-alpha-induced inflammatory responses by leukocytapheresis therapy in patients with ulcerative colitis. J Gastroenterol 2004;39:1150-1157.
27. Kanai T, Makita S, Kawamura T, Nemoto Y, Kubota D, Nagayama K, et al. Extracorporeal elimination of TNF-alpha-producing CD14(dull)CD16(+) monocytes in leukocytapheresis therapy for ulcerative colitis. Inflamm Bowel Dis 2007;13:284-290.
28. Yagi Y, Andoh A, Inatomi O, Bamba S, Tsujikawa T, Fujiyama Y, et al. Modulation of platelet aggregation responses by leukocytapheresis therapy in patients with active ulcerative colitis. J Gastroenterol 2006;41:540-546.
29. Hanai H, Iida T, Takeuchi K, Watanabe F, Maruyama Y, Kikuyama M, et al. Decrease of reactive-oxygen-producing granulocytes and release of IL-10 into the peripheral blood following leukocytapheresis in patients with active ulcerative colitis. World J Gastroenterol 2005;11:3085-3090.
30. Suzuki K, Sugimura K, Hasegawa K, Yoshida K, Suzuki A, Ishizuka K, et al. Activated platelets in ulcerative colitis enhance the production of reactive oxygen species by polymorphonuclear leukocytes. Scand J Gastroenterol 2001;36:1301-1306.